Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Raderer

Showing results (151-160 of 264) with videos related to

Pageof 27
Sort By:
Haematologica|September 18, 2012
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose TumortherapieMarlene Troch, Barbara Kiesewetter, Wolfgang Willenbacher, et al.
The Oncologist|January 11, 2024
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET StudyMarianne Pavel, Harald Lahner, Dieter Hörsch, et al.
Plos One|August 1, 2014
Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patientsBarbara Kiesewetter, Julius Lukas, Andreas Kuchar, et al.
Pharmacological Research|October 13, 2025
K<sub>V</sub>11.1 (hERG1)-centered macromolecular membrane complexes regulate proliferation in B cell lymphomas and constitute novel pharmacological targetsCesare Sala, Jessica Iorio, Claudia Duranti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancerWerner Scheithauer, Gabriela V Kornek, Markus Raderer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factorGabriela V Kornek, Karin Haider, Werner Kwasny, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 28, 2003
111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative studyShuren Li, Amir Kurtaran, Mei Li, et al.
Oncology|January 16, 2007
Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphomaMarkus Raderer, Stefan Wohrer, Berthold Streubel, et al.
Wiener Klinische Wochenschrift|August 19, 2021
SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic : Conclusions for crisis response at a high-volume oncology centerJulia M Berger, Margaretha Gansterer, Wolfgang Trutschnig, et al.
Clinical & Experimental Metastasis|May 23, 2023
Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancerLadislaia Wolff, Ariane Steindl, Petar Popov, et al.
Pageof 27

Showing results (151-160 of 264) with videos related to

Sort By:
Pageof 27
Haematologica|September 18, 2012
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose TumortherapieMarlene Troch, Barbara Kiesewetter, Wolfgang Willenbacher, et al.
The Oncologist|January 11, 2024
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET StudyMarianne Pavel, Harald Lahner, Dieter Hörsch, et al.
Plos One|August 1, 2014
Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patientsBarbara Kiesewetter, Julius Lukas, Andreas Kuchar, et al.
Pharmacological Research|October 13, 2025
K<sub>V</sub>11.1 (hERG1)-centered macromolecular membrane complexes regulate proliferation in B cell lymphomas and constitute novel pharmacological targetsCesare Sala, Jessica Iorio, Claudia Duranti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancerWerner Scheithauer, Gabriela V Kornek, Markus Raderer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factorGabriela V Kornek, Karin Haider, Werner Kwasny, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 28, 2003
111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative studyShuren Li, Amir Kurtaran, Mei Li, et al.
Oncology|January 16, 2007
Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphomaMarkus Raderer, Stefan Wohrer, Berthold Streubel, et al.
Wiener Klinische Wochenschrift|August 19, 2021
SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic : Conclusions for crisis response at a high-volume oncology centerJulia M Berger, Margaretha Gansterer, Wolfgang Trutschnig, et al.
Clinical & Experimental Metastasis|May 23, 2023
Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancerLadislaia Wolff, Ariane Steindl, Petar Popov, et al.
Pageof 27